Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Number of holders
-
211
-
Total 13F shares, excl. options
-
81,758,941
-
Shares change
-
+5,439,765
-
Total reported value, excl. options
-
$2,069,347,401
-
Value change
-
+$120,257,967
-
Put/Call ratio
-
47%
-
Number of buys
-
124
-
Number of sells
-
96
-
Price
-
$25.31
Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q2 2023
277 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of 30 Jun 2023.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) had 211 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 81,758,941 shares of stock of the company.
Largest 10 holders included Capital World Investors, BlackRock Inc., Palo Alto Investors LP, JPMORGAN CHASE & CO, VANGUARD GROUP INC, Polar Capital Holdings Plc, Thrivent Financial for Lutherans, ALLIANCEBERNSTEIN L.P., FRANKLIN RESOURCES INC, and STATE STREET CORP.
This table shows the top 211 institutional shareholders of the security as of 30 Jun 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.